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ABSTRACT 
Aim: To study the course of asymptomatic 
testicular adrenal rest tumours in patients with 
congenital adrenal hyperplasia (CAH) and the 
association between tumour changes and gluco-
corticoid therapy adjustments. 
Patients and Methods: Fifteen male patients with 
CAH (21-hydroxylase deficiency), in whom 
asymptomatic testicular adrenal rest tumours 
had been found at a baseline investigation, 
underwent scrotal ultrasonography and venous 
blood sampling (for LH, FSH and testosterone) 
on average 2.6 years later. The level of hormonal 
control was assessed by measurement of andro-
stenedione in three diurnal saliva samples. Data 
on changes in glucocorticoid therapy since 
baseline were obtained from the patients' 
records. 
Results: Tumour decrease, defined as >30% 
decrease in the sum of the longest diameter(s) of 
the lesion(s), was found in six patients; tumour 
increase, defined as >20% increase, in six and 
stable tumours in three patients. All three 
patients with overtreatment showed tumour 
decrease and of the six patients with under-
treatment only one showed tumour decrease. 
Tumour increase was not only observed in 
undertreated patients but also in patients with 
adequate treatment. Changing the night dose of 
hydrocortisone into dexamethasone, to obtain 
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prolonged ACTH suppression, had resulted in 
better adrenal suppression in only one patient. 
Conclusions: Tumour decrease could be achiev-
ed by aiming at adrenal oversuppression, but 
the required high glucocorticoid doses may 
induce side effects. In asymptomatic tumours in 
young male patients with CAH, a practical 
guideline could be to optimise adrenal suppres-
sion to a maximal tolerable glucocorticoid dose 
and to offer analysis and cryopreservation of 
semen as soon as the patient can be motivated. 
. r •« 
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INTRODUCTION 
Congenital adrenal hyperplasia (CAH) is an 
inherited disorder of adrenal steroidogenesis, 
usually caused by 21-hydroxylase deficiency. Corti-
sol (and aldosterone) production is decreased or 
absent, resulting in increased pituitary secretion of 
corticotropin (ACTH) and, consequently, excess 
adrenal androgen production. Treatment consists of 
administration of glucocorticoids (and mineralo-
corticoids) for Cortisol (and aldosterone) substitu-
tion and suppression of excess androgen production 
by re-establishing the negative feedback on ACTH 
secretion1. 
In male patients with CAH, testicular adrenal 
rest tumours are increasingly reported at all ages2"4. 
The tumours are considered to be aberrant adrenal 
tissue that has descended with the testes and has 
become hyperplastic due to ACTH stimulation. The 
recommended treatment consists of increasing the 
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glucocorticoid dose to suppress ACTH secretion5. 
Most reports on treatment describe patients who 
experienced testicular pain or subfertility. In these 
symptomatic cases increasing the dose of gluco-
corticoids is justified and often successful6'7. In 
asymptomatic cases, however, this approach is not 
self-evident because the relevance of the tumours is 
unknown and treatment with high glucocorticoid 
doses for a prolonged time induces side effects, 
such as weight gain, striae and osteoporosis. In this 
situation, the negative effects of increasing the 
glucocorticoid dose may exceed the benefits. 
In a previous study, we have reported a high 
prevalence of testicular adrenal rest tumours in 
postpubertal male patients with CAH4. The tumours 
were all asymptomatic and the patients did not have 
immediate fertility interest. To study the course of 
asymptomatic testicular adrenal rest tumours, we 
re-evaluated the tumours on average 2.6 years after 
the baseline investigation. In addition, we studied 
the association between tumour changes and gluco-
corticoid therapy adjustments in the follow-up 
period. 
PATIENTS AND METHODS 
Patients 
At the baseline investigation, all male patients 
who were seen in our centre for treatment of CAH 
due to 21-hydroxylase deficiency and who were 16 
years or older, had participated (η = 17)4. In 16 of 
them, testicular adrenal rest tumours had been 
found. At the follow-up investigation, 15 of these 
16 patients were included; the other patient did not 
want to have scrotal ultrasonography again. Patient 
characteristics have been extensively described 
elsewhere4 and, for comparison, the same patient 
numbers are used. In 12 of the 15 patients, salt-
wasting CAH had been diagnosed in the first year 
of life; three other patients had presented with 
simple virilizing CAH at the age of 2.9 years (one 
patient) and 6.2 years (two patients). In all 15 
patients the diagnosis had been confirmed by DNA 
analysis. The patients were treated from the time of 
CAH diagnosis with glucocorticoids (and mineralo-
corticoids) and were followed up regularly by a(n) 
(paediatric) endocrinologist. 
Baseline investigation 
The baseline investigation in 1998 was cross-
sectional and consisted of scrotal ultrasonography, 
determination of plasma testosterone, serum LH 
and FSH, salivary 17-hydroxyprogesterone and 
androstenedione and semen analysis4. 
Period between baseline and follow-up investigation 
Routine clinic visits (2-4 times a year) consisted 
of history taking, physical examination (weight, 
blood pressure, Cushing signs) and determination 
of 17-hydroxyprogesterone and androstenedione in 
diurnal saliva samples. Analysis and cryopreserva-
tion of semen was offered to the patients. Semen 
analysis was performed according to WHO guide-
lines8. 
Data on glucocorticoid therapy between baseline 
and follow-up investigation were retrospectively 
obtained from the patient records. To calculate the 
total glucocorticoid dose, doses of dexamethasone 
were converted into hydrocortisone equivalents (30 
mg hydrocortisone = 0.75 mg dexamethasone)9. 
Follow-up investigation 
The follow-up investigation in 2001, 2.6 ± 0.2 
years (mean ± SD) after the baseline investigation, 
consisted of scrotal ultrasonography, venous blood 
sampling and saliva sampling. Grayscale and colour 
Doppler ultrasonography were performed as at the 
baseline investigation4, by the same staff radio-
logist (GJJ), who was not informed about the 
therapeutic regimens. Ultrasonography results at 
follow up were compared to those at baseline: 
tumour decrease was defined as >30% decrease in 
the sum of the longest diameter(s) of the lesion(s), 
tumour increase was defined as >20% increase in 
the sum and the remaining category was called 
stable tumour. These criteria were derived from the 
RECIST (Response Evaluation Criteria in Solid 
Tumours) criteria10. 
Venous blood sampling was performed at 09.00 
h to measure levels of testosterone, LH and FSH. 
Patients had taken their regular morning medica-
tion. Plasma testosterone was measured by RIA 
after a paper chromatographic purification step"; 
the normal range in adult males is 11-45 nmol/1. 
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Serum LH and FSH were quantitatively determined 
(AxSYM, Abbott Laboratories, USA); the normal 
range in adult males is 1.4-8.5 U/l for LH and 
1.5-11 U/l for FSH. 
Levels of salivary 17-hydroxyprogesterone and 
androstenedione 
Measurement of salivary levels of 17-hydroxy-
progesterone and androstenedione is routinely used 
to assess hormonal control in patients with CAH12. 
Patients collected three saliva samples, by saliva-
tion into plastic cups, 2 days before the follow-up 
investigation, at 08.00 h, 12.00 h, and 20.00 h, 
before every regular glucocorticoid intake. In the 
samples, 17-hydroxyprogesterone and androstene-
dione levels were determined by RIA after a paper 
chromatographic purification step13. The mean 
androstenedione level of the three samples was 
calculated to assess hormonal control: under-
treatment was defined as a mean level above the 
reference morning (08.00 h) range (>0.63 nmol/1), 
overtreatment below this range (<0.14 nmol/1), and 
adequate treatment within the reference range, i.e. 
0.14-0.63 nmol/14. 
RESULTS 
Results of the follow-up investigation 
Testicular tumours had increased in six patients 
(6/15,40%). In one of these patients (#8), the initial 
tumours in one testis had disappeared, and in the 
contralateral testis, tumours had appeared. Tumours 
had decreased in six patients (6/15, 40%), and were 
stable in three patients (3/15, 20%) (Table 1). 
Plasma testosterone levels were below the 
normal range in four of the 15 patients (Table 2). 
Three patients had decreased levels of both serum 
LH and FSH (hypogonadotropism); in two of them 
(#3, 4) this had been found also at baseline 
investigation; in the third patient serum LH had 
been normal and serum FSH had been elevated at 
baseline (#6). 
Overtreatment was found in three patients, 
undertreatment in six patients and adequate treat-
ment in six patients (Table 2). The patients who 
were judged to be overtreated at the baseline 
investigation were still overtreated or adequately 
treated (#7, 9, 13). The patients who were under-
treated at baseline were still undertreated (#3, 4, 10, 
17), except for one patient who was now over-
treated (#2). 
Glucocorticoid therapy between baseline and follow-
up investigation 
Data on glucocorticoid therapy are shown in 
Table 3. In five patients (#3, 9, 10, 11, 13), the 
glucocorticoid dose had not changed during the 
follow-up period and in two patients (#4, 7) the 
glucocorticoid dose had been diminished compared 
to the baseline situation. In one patient (#2), the 
regimen of hydrocortisone 2 times a day (15 + 10 
mg) was changed into dexamethasone 3 times a day 
(0.25 + 0.25 + 0.25 mg), to improve semen quality 
after oligoasthenoteratozoospermia was found and 
he and his wife wanted to have a child. In seven 
patients (#5, 6, 8, 12, 15, 16, 17), the hydrocorti-
sone regimen (3 times a day) had been changed into 
hydrocortisone in the morning (and afternoon) and 
dexamethasone in the evening. Changes in body 
mass index between baseline and follow-up investi-
gation did not show a significant correlation with 
changes in glucocorticoid dose (Spearman rank, 
ρ >0.2). 
Relationship between tumour change, suppression of 
salivary androstenedione and glucocorticoid therapy 
Tumour decrease was found in all three patients 
who were overtreated at the follow-up investiga-
tion; they were at baseline overtreated (n = 1), 
adequately treated (n = 1) or undertreated (n = 1). 
Tumour decrease was also found in two patients 
who were adequately treated at the follow-up 
investigation and overtreated at baseline, and in one 
patient who was still, although to a lesser degree, 
undertreated (#17). 
Tumour increase was found in three patients 
who were undertreated at the follow-up investiga-
tion and who were at baseline undertreated (n = 1) 
or adequately treated (n = 2). Tumour increase was 
also found in three patients who were adequately 
treated on both occasions. 
Stable tumours were found in one patient with 
one small tumour who was adequately treated on 
both occasions (#11) and in two patients with large 
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TABLE 2 
Plasma levels of testosterone, serum levels of LH and FSH, mean salivary levels of 17-hydroxyprogesterone 
(17-OHP) and androstenedione (adione) in 15 male patients with 21-hydroxylase deficiency 
Patient # Plasma 
testosterone 
(nmol/1) 
Serum LH 
(U/l) 
Serum FSH 
(U/l) 
Mean salivary 
17-OHP 
(nmol/1)a 
Mean salivary 
adione 
(nmol/1)a 
2 7.0 2.5 11.1 3.90 0.03 1.80 0.08 
3 27.0 <0.2 <0.2 6.24 7.26 2.93 4.80 
4 9.4 0.2 0.6 8.30 9.37 4.23 5.87 
5 12.0 5.8 9.4 0.83 0.13 0.22 0.09 
6 22.5 0.3 1.4 1.29 14.5 0.22 3.33 
7 16.0 3.8 14.6 0.02 0.05 0.12 0.10 
8 26.0 5.0 5.0 0.95 5.13 0.37 0.97 
9 12.0 2.9 1.9 0.01 1.73 0.06 0.45 
10 7.0 0.5 1.6 5.60 5.91 1.40 1.52 
11 9.0 9.6 16.7 1.19 1.30 0.19 0.16 
12 15.0 2.3 2.7 0.43 0.17 0.30 0.14 
13 21.0 8.6 10.8 0.06 0.38 0.10 0.17 
15 19.0 2.6 7.9 0.09 0.08 0.20 0.21 
16 27.0 4.4 6.7 0.76 0.19 0.25 0.18 
17 17.0 1.0 4.5 4.90 2.73 1.05 0.66 
Normal values 11.0-45.0 1.4-8.5 1.5-11.0 0.05-0.36 b 0.14-0.63" 
Numbers in italics are the levels at the baseline investigation. 
' Salivary levels of 17-OHP and adione are mean levels from 3 samples (see Methods). 
b Normal morning (08.00 h) levels; undertreatment was defined as a mean salivary adione level >0.63 nmol/1, 
overtreatment <0.14 nmol/1, adequate treatment 0.14-0.63 nmol/1. 
bilateral tumours (#3, 4) who were undertreated on 
both occasions. 
The nine patients who at the time of the follow-
up investigation had hydrocortisone in the morning 
(and afternoon) and dexamethasone at night, 
showed at the follow-up investigation overtreat-
ment (n = 1), adequate treatment (n = 5) or under-
treatment (n = 3). 
The patient who was treated with dexametha-
sone 0.75 mg daily to improve fertility (#2), 
showed overtreatment at the follow-up investiga-
tion (undertreatment at baseline), decreased tumour 
VOLUME 17, NO. 4, 2004 
size and improved semen quality. Spontaneous 
conception occurred a few weeks after the follow-
up investigation and a healthy daughter has been 
born. Confirmation of parenthood was not per-
formed. 
DISCUSSION 
The aim of this investigation was to study the 
course of asymptomatic testicular adrenal rest 
tumours in male patients with CAH, and the 
association between tumour change and gluco-
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corticoid therapy adjustments. This follow-up 
investigation, 2.6 years after a baseline investiga-
tion, showed tumour decrease in 40% of the 
patients and increase in 40%. There was an 
association between tumour change and hormonal 
control: all three patients with overtreatment at 
follow-up showed tumour decrease and of the six 
patients with undertreatment only one showed 
tumour decrease. Tumour increase, on the other 
hand, was not only observed in undertreated 
patients but also in patients who were adequately 
treated at follow-up. These results suggest, like 
previous reports on symptomatic tumours, that 
tumour shrinkage can be achieved effectively by 
aiming at overtreatment. If the tumour does not 
shrink despite overtreatment or if there is persistent 
azoospermia despite tumour shrinkage, surgical 
intervention should be considered7. 
In one patient, who had bilateral testicular 
tumours and oligoasthenoteratozoospermia, the 
glucocorticoid dose had been increased as recom-
mended in symptomatic tumours5, because he and 
his wife wished to have a child. The tumour 
decrease and improvement of semen quality corres-
pond with previous reports on successful treatment 
of symptomatic tumours in males with CAH6,7. 
Despite successful conception, testicular function 
was still not normal, based on the slightly increased 
serum FSH level and the decreased plasma 
testosterone level. 
In the other 14 patients, our approach was aimed 
at tumour decrease by optimising adrenal suppres-
sion with glucocorticoid therapy adjustments, but 
avoiding additional glucocorticoid side effects such 
as weight gain and striae. In the patients with a 
hydrocortisone regimen (2-3 times a day) at 
baseline, replacing the night dose of hydrocortisone 
by dexamethasone was considered. Dexamethasone 
has a longer half life compared to hydrocortisone 
and it could, when given in the evening, lead to a 
longer suppression of the hypothalamo-pituitary-
adrenal axis during the night14. However, this 
change of the glucocorticoid regimen resulted in 
better hormonal control in only one patient. In two 
patients there was even worse suppression: ade-
quate treatment at baseline and undertreatment at 
follow-up, despite obviously increased glucocorti-
coid dose. This paradoxical result could suggest 
poor compliance or secretion of androstenedione by 
the testicular tumour itself. In that case, the andro-
stenedione level is not only the result of adrenal 
activity but also of tumour activity and cannot be 
used to assess adrenal suppression15'16. 
The adrenal rest tumours may not only be 
sensitive to hormonal control but also to other 
factors. This is illustrated by two cases of tumour 
regression despite worse adrenal suppression (over-
treatment at baseline, adequate treatment at follow 
up) and the observation in another patient that 
unilateral tumours had disappeared and new 
tumours had appeared in the contralateral testes. 
Interestingly, Benvenga et al. suggested, from 
observations in a young male patient with CAH, 
that testicular adrenal rest tumours may not only be 
sensitive to ACTH but also to LH17. 
In three patients, hypogonadotropism was found 
and they were all undertreated. This corresponds to 
the hypothesis that hypogonadotropism in males 
with CAH is caused by suppression of the 
hypothalamo-pituitary-gonadal axis by adrenal 
androgens, both directly and after conversion to 
1X 
estrogens . Thus, in undertreated patients, fertility 
may not only be disturbed by testicular tumours but 
also by secondary hypogonadotropism. 
This study provides data about the course of 
asymptomatic testicular adrenal rest tumours in 
males with CAH and the association with hormonal 
control, but there are some limitations. The 
adjustments in the glucocorticoid therapy during 
the follow-up period were based on the general 
principle of optimising adrenal suppression, but 
were made in every patient individually. There was 
no randomisation or standardised intervention, 
which makes the retrospective assessment of the 
relationship between tumour change and inter-
vention difficult. Furthermore, the judgement of 
hormonal control was based on salivary androstene-
dione levels on only one day, which does not 
necessarily correspond with the hormonal control 
during the complete follow-up period. Finally, the 
outcome measure tumour change is only a surrogate 
for the major interest, which is future fertility. We 
considered, however, that tumour growth is an 
important measure because it will finally affect 
fertility by causing compression of residual testi-
cular tissue and obstruction of semen flow. 
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In conclusion, treating asymptomatic testicular 
adrenal rest tumours in young patients with CAH is 
difficult because the natural course of the tumours 
and their impact on fertility are unknown, the 
patient may not yet be interested in fertility, and, 
furthermore, treatment with increased doses of 
glucocorticoids can induce side effects. The 
tumours should be detected as early as possible, 
and therefore we would recommend performing 
testicular ultrasonography in all male patients with 
CAH on a regular basis (e.g. every 1-2 years) from 
the onset of puberty (testicular volume of 4 ml). In 
case of poor hormonal control, testicular ultrasono-
graphy can be considered even before the onset of 
puberty. Our observations suggest that tumour 
decrease can be obtained by aiming at adrenal 
oversuppression, but this usually requires high 
glucocorticoid doses and induces side effects. With 
asymptomatic tumours in young male patients with 
CAH, a practical guideline could be to optimise 
adrenal suppression to a maximal tolerable gluco-
corticoid dose and to offer analysis and cryo-
preservation of semen as soon as the patient can be 
motivated. 
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